Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology · HER2-Negative Breast Cancer

Long-Term Monitoring and Living Well

At a Glance

Long-term HER2-negative breast cancer care combines treatment monitoring with quality-of-life support: report fever, breathing changes, severe diarrhea, or one-leg swelling promptly; keep up with recommended blood tests and bone-density scans; and use a plan for scan-related anxiety.

Living with HER2-negative breast cancer often means transitioning into a “marathon” phase of care. Whether you are taking daily pills for a decade or receiving ongoing infusions for metastatic disease, the focus shifts to balancing treatment effectiveness with your quality of life [1][2]. Monitoring is not just about looking for the cancer; it is about keeping you safe while you are on these powerful medications [3].

When to Seek Immediate Help (Red Flags)

While most side effects can be managed at home or during a scheduled visit, some symptoms require urgent medical attention. Do not wait until your next appointment if you experience the following:

Tier 1: Immediate Action Required

  • Fever of 100.4°F (38.0°C) or higher: This is an urgent oncology call, particularly during chemotherapy, as it could signal neutropenic fever. Call your oncology 24-hour line immediately and follow their emergency plan. Go to the ER if directed. Do not take fever-reducing medicine until you have spoken to a professional [4][5].
  • Call 911 for severe symptoms: Such as sudden, severe shortness of breath, crushing chest pain, fainting, or slurred speech, which can signal a pulmonary embolism, heart rhythm issue, or other critical event [6][7].

Tier 2: Call Your Care Team Today

  • Severe Diarrhea: If you have more than 4–6 bowel movements above your baseline, severe abdominal pain, blood in your stool, or cannot keep liquids down [3][8].
  • New or Worsening Cough: Even a mild, dry cough can be an early sign of lung toxicity from ADCs or CDK4/6 inhibitors [9][7].
  • Unusual Swelling in One Leg: This could be a deep vein thrombosis (DVT), a blood clot that requires prompt treatment [6].

Tier 3: Discuss at Your Next Visit

  • Mild fatigue, joint aches, or “brain fog.”
  • Occasional hot flashes or vaginal dryness [1].
  • Mild skin rashes or dry eyes.

Managing Your Medications

Each class of drug has its own “safety profile” that requires specific tests:

  • CDK4/6 Inhibitors and Chemotherapy: You will need frequent blood tests to check your Absolute Neutrophil Count (ANC) (the white blood cells that fight infection). When counts fall (neutropenia), your risk of infection increases. Wash your hands frequently and reduce exposure to sick contacts, but you do not need to become completely isolated. Your team may use dose delays or growth-factor injections to manage this [3].
  • Antibody-Drug Conjugates (Enhertu, Trodelvy): These require proactive lung monitoring, though routine asymptomatic CT surveillance is not identical for every drug or institution. Trastuzumab deruxtecan has a particularly important ILD/pneumonitis risk. Promptly report any new cough or breathlessness so a same-day assessment and appropriate imaging can be ordered [7][10].
  • Everolimus (Afinitor): This drug is known for causing stomatitis (mouth sores). Your doctor may prescribe a steroid mouthwash to use preventatively to stop these sores before they start [3].

Protecting Your Bone Health

Hormone therapies, especially aromatase inhibitors, lower estrogen levels, which can lead to bone thinning (osteoporosis) and a higher risk of fractures [11][12].

  • Monitoring: Most patients should have a DXA scan (bone density test) at the start of treatment and every 1–2 years afterward [12].
  • Treatment: Your doctor may recommend bone-strengthening medications like bisphosphonates (zoledronic acid) or denosumab (Prolia/Xgeva) [13][14].
    • Crucial Note: If you are on denosumab, never stop without a planned transition arranged by your clinician. Stopping suddenly can cause a rapid “rebound” of bone loss and lead to spinal fractures. Make sure to monitor your calcium levels and maintain regular dental checks [15].
  • Lifestyle: Aim for 1,200 mg of calcium daily (from food and supplements) and 800–1,000 IU of Vitamin D, alongside weight-bearing exercises like walking or light lifting [12].

The Psychological Toll: “Scanxiety”

It is completely normal to feel a spike in fear and anxiety in the days leading up to a scan—a phenomenon often called scanxiety [16]. It helps to know what surveillance to expect based on your stage: routine CT/PET scans and tumor markers are generally not used to look for recurrence in an asymptomatic early-stage patient, where follow-up relies on clinical exams and annual mammography. In contrast, metastatic disease is commonly imaged to assess treatment response.

  • Acknowledge the Fear: Fear of recurrence is one of the most common challenges for survivors [17]. Research shows that Mindfulness-Based Cognitive Therapy (MBCT) and Acceptance and Commitment Therapy (ACT) are highly effective at helping patients manage these feelings [18][19].
  • Practical Steps: Ask your team exactly how and when you will receive your results. Knowing you will get a call on Tuesday can help you manage the silence of Monday [20].
  • Limit “Information Overload”: While it is tempting to check your patient portal every hour, try to wait for your doctor’s interpretation to avoid unnecessary panic over technical language in a report [16].

Your oncology team is your partner in this long-term journey. Keeping a symptom diary and being honest about how you feel—both physically and emotionally—helps them tailor your care to keep you as healthy and comfortable as possible [1].

Common questions in this guide

When should I call my oncology team about a fever during HER2-negative breast cancer treatment?
Call your oncology team's 24-hour line immediately for a temperature of 100.4°F (38°C) or higher, especially during chemotherapy. Follow their emergency instructions and do not take fever-reducing medicine before speaking with a clinician unless they tell you to.
Which treatment symptoms require emergency help?
Call 911 for sudden, severe shortness of breath, crushing chest pain, fainting, or slurred speech. These symptoms can signal a serious clot, heart rhythm problem, or another critical event and should not wait for a scheduled visit.
How often do I need bone-density testing during hormone therapy?
Some hormone treatments, especially aromatase inhibitors, can lower estrogen and weaken bones. Most patients are advised to have a DXA scan when treatment starts and every 1–2 years afterward, but your clinician should set the schedule and decide whether zoledronic acid or denosumab is appropriate. Do not stop denosumab without a planned transition.
Why should I report a new cough while taking Enhertu or other cancer medicines?
New or worsening cough or breathlessness can be an early sign of lung inflammation or toxicity from some antibody-drug conjugates, including trastuzumab deruxtecan (Enhertu), and from some CDK4/6 inhibitors. Contact your care team promptly for assessment; severe breathing difficulty requires emergency help.
What tests may be part of long-term monitoring for HER2-negative breast cancer?
Monitoring depends on your medicines and stage. Blood counts, including the absolute neutrophil count, may be needed with chemotherapy or CDK4/6 inhibitors; lung assessment may be needed with some antibody-drug conjugates; and an ECG or heart imaging may be considered for certain drugs.
How can I manage scanxiety before follow-up imaging?
Scanxiety is common before scans. Ask when and how you will receive results, limit repeated portal checking until your clinician interprets the report, and consider support or therapies such as mindfulness-based cognitive therapy or acceptance and commitment therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific monitoring schedule for blood counts, and should I have an ECG or heart scan based on the drugs I'm taking?
  2. 2.When should my next DXA bone density scan be, and am I a candidate for a bone-strengthening drug like zoledronic acid or denosumab?
  3. 3.What is the plan for monitoring my lung health while on antibody-drug conjugates (like Enhertu) or CDK4/6 inhibitors?
  4. 4.If I am having trouble with the side effects of hormone therapy, can we discuss a 'drug holiday' or a dose adjustment before I consider stopping altogether?
  5. 5.Can you help me understand which symptoms I might experience are 'normal' and which ones warrant a call to your office immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

    Runowicz CD, Leach CR, Henry NL, et al.

    CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.

    PMID: 26641959
  2. 2

    Fear of Cancer Recurrence: A Practical Guide for Clinicians.

    Butow P, Sharpe L, Thewes B, et al.

    Oncology (Williston Park, N.Y.) 2018; (32(1)):32-8.

    PMID: 29447419
  3. 3

    Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.

    Thill M, Schmidt M

    Therapeutic advances in medical oncology 2018; (10()):1758835918793326 doi:10.1177/1758835918793326.

    PMID: 30202447
  4. 4

    Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis.

    Pathak N, Di Iorio M, Gimenez DM, et al.

    Critical reviews in oncology/hematology 2025; (213()):104787 doi:10.1016/j.critrevonc.2025.104787.

    PMID: 40466817
  5. 5

    Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.

    Schäffler H, Jakob D, Huesmann S, et al.

    Geburtshilfe und Frauenheilkunde 2024; (84(9)):855-865 doi:10.1055/a-2375-5194.

    PMID: 39229630
  6. 6

    Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis.

    Hoo YY, Sia WW, Jaya-Prakason S, et al.

    Cancer treatment reviews 2026; (142()):103069 doi:10.1016/j.ctrv.2025.103069.

    PMID: 41422771
  7. 7

    Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.

    Chiu JWY, Lee SC, Ho JC, et al.

    Drug safety 2023; (46(10)):927-949 doi:10.1007/s40264-023-01328-x.

    PMID: 37552439
  8. 8

    Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.

    Pedersini R, Buffoni M, Petrelli F, et al.

    Clinical breast cancer 2024; (24(5)):411-420 doi:10.1016/j.clbc.2024.04.003.

    PMID: 38734491
  9. 9

    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.

    Raschi E, Fusaroli M, Ardizzoni A, et al.

    Breast cancer research and treatment 2021; (186(1)):219-227 doi:10.1007/s10549-020-06001-w.

    PMID: 33150548
  10. 10

    Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

    Swain SM, Nishino M, Lancaster LH, et al.

    Cancer treatment reviews 2022; (106()):102378 doi:10.1016/j.ctrv.2022.102378.

    PMID: 35430509
  11. 11

    The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

    Ramchand SK, Cheung YM, Yeo B, Grossmann M

    The Journal of endocrinology 2019; (241(3)):R111-R124.

    PMID: 30991355
  12. 12

    Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.

    Grossmann M, Ramchand SK, Milat F, et al.

    Clinical endocrinology 2018; (89(3)):280-296 doi:10.1111/cen.13735.

    PMID: 29741296
  13. 13

    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

    Dhesy-Thind S, Fletcher GG, Blanchette PS, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(18)):2062-2081 doi:10.1200/JCO.2016.70.7257.

    PMID: 28618241
  14. 14

    Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

    Gnant M, Pfeiler G, Dubsky PC, et al.

    Lancet (London, England) 2015; (386(9992)):433-43.

    PMID: 26040499
  15. 15

    Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

    Tsourdi E, Zillikens MC, Meier C, et al.

    The Journal of clinical endocrinology and metabolism 2020; doi:10.1210/clinem/dgaa756.

    PMID: 33103722
  16. 16

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  17. 17

    Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.

    Park S, Sato Y, Takita Y, et al.

    Journal of pain and symptom management 2020; (60(2)):381-389 doi:10.1016/j.jpainsymman.2020.02.017.

    PMID: 32105790
  18. 18

    The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

    Lyu MM, Siah RC, Lam ASL, Cheng KKF

    Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

    PMID: 35696315
  19. 19

    Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.

    Johns SA, Stutz PV, Talib TL, et al.

    Cancer 2020; (126(1)):211-218 doi:10.1002/cncr.32518.

    PMID: 31539169
  20. 20

    Women's experiences and preferences regarding breast imaging after completing breast cancer treatment.

    Brandzel S, Rosenberg DE, Johnson D, et al.

    Patient preference and adherence 2017; (11()):199-204 doi:10.2147/PPA.S122244.

    PMID: 28203064

This page is for informational purposes only and does not constitute medical advice. It explains monitoring and warning signs for HER2-negative breast cancer; contact your oncology team promptly about concerning symptoms or medication questions.

Get notified when new evidence is published on Her2-receptor negative breast cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.